|
With revenue of about $40 million a year, EDAP should trade between $15 to $20 per share. Look at the similar stocks, such as, ISRG which is traded with 10 times of revenue, and ALGN which is valued at 4 times of revenue. With the potential of HIFU, EDAP is way under valued.
The Q3 report is coming. Let's see it rewards the share holders with a profitable quarter. Rating :
 (2 Ratings) |
47/Male |
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
0.03